Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review0167 has been discontinued.
View all Non-selective Ionotropic Glutamate products.Antagonist at non-NMDA receptors.
分子量 | 379.11 |
储存 | Store at RT |
CAS Number | 94856-92-5 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Davies et al (1984) Phosphonodipeptides and piperazine derivatives as antagonists of amino acid-induced and synaptic excitation in mammalian and amphibian spinal cord. Neurosci.Lett. 52 79 PMID: 6098881
Evans et al (1987) A comparison of excitatory amino acid antagonists acting at primary afferent C fibres and motoneurones of the isolated spinal cord of the rat. Br.J.Pharmacol. 91 531 PMID: 3038242
Watkins et al (1990) Experiments with kainate and quisqualate agonists and antagonists in relation to the sub-classification of non-NMDA receptors. Excitatory amino acids and neuronal plasticity. Ed 49
关键词: 1-(4-Bromobenzoyl)piperazine-2,3-dicarboxylic acid sodium salt, 1-(4-Bromobenzoyl)piperazine-2,3-dicarboxylic acid sodium salt supplier, Non-selective, Ionotropic, Glutamate, 0167, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。
目前没有 1-(4-Bromobenzoyl)piperazine-2,3-dicarboxylic acid sodium salt 的引用文献。
目前没有该产品的评论。 Be the first to review 1-(4-Bromobenzoyl)piperazine-2,3-dicarboxylic acid sodium salt and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.